



Biocon Limited

20th KM, Hosur Road

Electronic City

Bangalore 560 100, India

T: 91 80 2808 2808

F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/164

January 21, 2026

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 532523	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol - Biocon
--	---

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to our intimation dated December 06, 2025, with respect to the outcome of the meeting of the Board of Directors (“**Board**”) held on December 06, 2025, whereby the Board had approved the acquisition of equity shares of Biocon Biologics Limited (“**BBL**”), an unlisted material subsidiary of the Company held by various Investors, including acquisition of 14,36,69,382 equity shares from Mylan Inc. by way of cash consideration of USD 400 million.

In this regard and in continuation of our intimation dated January 05, 2026 in respect of completion of acquisition of 7,18,34,691 equity shares from Mylan Inc. out of the aforesaid acquisition of 14,36,69,382 equity shares, please be informed that the Company has today i.e. on January 21, 2026 completed the acquisition of balance 7,18,34,691 equity shares of BBL from Mylan Inc. against cash consideration of USD 200 million.

Post the aforesaid acquisition, the Company holds ~98% of the paid-up equity share capital of BBL on a fully diluted basis.

The above-mentioned information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

For **Biocon Limited**

Rajesh U. Shanoy

Company Secretary and Compliance officer

ICSI Membership Number: A16328